The FDA is pushing for a "black box" warning on labels of GlaxoSmithKline's diabetes drug Avandia to include information about the treatment's heart attack risk, officials familiar with the issue say. A GSK spokeswoman said the drug giant is "working diligently with the FDA to finalize the label" on Avandia, which already carries a "black box" warning about heart failure.

Related Summaries